Výsledky vyhledávání - "Katelyn N. Cutts"

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Autor: Luis-Emilio Garcia-Perez, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Katie D. Stewart, Katelyn N. Cutts

Publikováno v: Quality of Life Research

Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c15aa003fafb860c63db79688923fe1
https://doi.org/10.1007/s11136-021-02808-2

Zobrazit plný text záznamu

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Autor: Luis-Emilio Garcia-Perez, Karen G. Malley, Karin S. Coyne, Ryan T. Hietpas, Jessica B Jordan, Katie D. Stewart, Paula Wullenweber, Qianqian Wang, Maria Yu, Katelyn N. Cutts, Kristina S. Boye, Brooke M. Currie, Louis S. Matza, K. Jack Ishak

Publikováno v: Diabetes, Obesity & Metabolism

Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c91ebf876ff096bac4cb8eb55fdcb7b3
https://doi.org/10.1111/dom.13902

Zobrazit plný text záznamu

93-LB: Preferences and Health State Utilities Associated with Routes of Administration for Oral Semaglutide, Injectable Semaglutide, and Dulaglutide

Autor: Kristina S. Boye, Louis S. Matza, Katie D. Stewart, Katelyn N. Cutts, Luis E. García-Pérez, Kirsi Norrbacka

Publikováno v: Diabetes. 69

Objective: Previous studies have examined health state utilities (which are preference weightings for use in cost-effectiveness analyses) associated with injectable GLP-1 receptor agonists for treatment of type 2 diabetes (T2D). An oral formulation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e0adbde0cb2f3e8e464878359292d95
https://doi.org/10.2337/db20-93-lb

Zobrazit plný text záznamu

Cover Image, Volume 22, Issue 3

Autor: Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas, Luis‐Emilio García‐Pérez

Publikováno v: Diabetes, Obesity and Metabolism. 22

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d738775086a68ef761a545852a1c1a2
https://doi.org/10.1111/dom.13999

Zobrazit plný text záznamu

Health State Utilities Associated with Attributes of Weekly Injection Devices and Subdermal Implant for Treatment of Type 2 Diabetes

Autor: Maud Beillat, Anne M. Rentz, Katelyn N. Cutts, Kristina Yu-Isenberg, Kellie Washington

Publikováno v: Diabetes. 67

Cost-utility analyses include health utilities to compare medical treatments. Health utilities, ranging from 0 to 1, represent the strength of a patient’s preference for a drug profile or health-related outcome. Recently glucagon-like peptide-1 (GL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d54d563a2cc3f423e2f3822dd5d51b2
https://doi.org/10.2337/db18-1114-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání